Sung Woon Chung

Sung Woon Chung

Auto-generated profile, based on publicly available information

Sung Woon Chung

Department of Thoracic and Cardiovascular Surgery, Pusan National University Hospital, Pusan National University School of Medicine, 49241 Busan, Republic of Korea

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2015 in The Korean Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
MBMiju Bae
Miju Bae
SCSung Woon Chung
Sung Woon Chung
CLChung Won Lee
Chung Won Lee
JCJinseok Choi
Jinseok Choi
SSSeunghwan Song
Seunghwan Song
SKSang-Pil Kim
Sang-Pil Kim
Miju Bae, Sung Woon Chung, Chung Won Lee, Jinseok Choi, Seunghwan Song, and Sang-pil Kim. Korean Journal of Thoracic and Cardiovascular Surgery 2015;48:246-51. http://dx.doi.org/10.5090/kjtcs.2015.48.4.246

18 June 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
UHUp Huh
Up Huh
YTYoung Jin Tak
Young Jin Tak
SSSeunghwan Song
Seunghwan Song
SCSung Woon Chung
Sung Woon Chung
SSSang Min Sung
Sang Min Sung
HAHyo Yeong Ahn
Hyo Yeong Ahn
Background: Little is known of the effect of wearable devices on metabolic impairments in clinical settings. We hypothesized that a wearable device that can monitor and provide feedback on physical activity may help resolve metabolic syndrome. Objective: This study aimed to examine the objective effects of the use of these devices on metabolic syndrome resolution. Methods: Patients diagnosed with metabolic syndrome were recruited. Participants were prescribed regular walking using a wearable device (Coffee WALKIE +Dv.3, GC Healthcare CI, Korea) on their wrist for 12 weeks. Participants received self-feedback on the amount of their exercise through an app on their mobile phone. The information on physical activities of the participants was uploaded automatically to a website. Thus, a trained nurse could provide individuals with feedback regarding the physical activity via telephone consultation on alternate weeks. Blood pressure (BP), body composition, fasting plasma glucose, and lipid profiles were recorded. The primary outcome was metabolic syndrome resolution. The secondary outcome was an improvement in the components of metabolic impairment. Results: Of the 53 participants recruited, 20 participants with a median age of 46 (range 36-50) years completed the trial. There was no significant difference in the amount of calorie expenditure at weeks 4, 8, and 12. After 12 weeks, metabolic syndrome was resolved in 9 of 20 participants (45%), and the mean number of metabolic impairment components per person decreased from 3.4 to 2.9. Particularly, the mean systolic and diastolic BP decreased from mean 136.6 (SD 18.5) mm Hg to mean 127.4 (SD 19.5) mm Hg and from mean 84.0 (SD 8.1) mm Hg to mean 77.4 (SD 14.4) mm Hg (both P=.02), respectively. Conclusions: This study found that a 12-week intervention via feedback, based on a wearable physical activity monitor, helped metabolic syndrome patients to be more engaged in regular walking and it improved impaired metabolic components, especially in BP. However, some practical challenges regarding patients’ adherence and sustained engagement were observed.

24 September 2021 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
GKGun Jik Kim
Gun Jik Kim
HJHanna Jung
Hanna Jung
ELEunjo Lee
Eunjo Lee
SCSung Woon Chung
Sung Woon Chung
Histone deacetylase (HDAC) inhibitors have shown cardioprotective or renoprotective effects in various animal models. Our study proposed that the HDAC inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system (RAS) activity in rats with transverse aortic constriction (TAC)-induced pressure overload cardiac hypertrophy. Cardiac remodelling was evaluated using echocardiography. Cardiac hypertrophy was visualized with haematoxylin and eosin staining, and related gene (Nppa and Nppb) expression was quantified by quantitative real-time polymerase chain reaction (qRT-PCR). Cardiac and renal fibrosis were visualized with picrosirius red and trichrome staining, respectively. Fibrosis related gene (Collagen-1, Collagen-3, Ctgf, and Fibronectin) expression was determined by qRT-PCR. Serum concentrations of RAS components (renin, angiotensin II, and aldosterone) were quantified by enzyme-linked immunosorbent assay and related gene (Renin and Agtr1) expression was determined by qRT-PCR. TAC-induced pressure overload cardiac hypertrophy, which mimics hypertensive heart disease, increased cardiac remodelling, cardiac hypertrophy, and fibrosis in our rat models. Upon treatment with mocetinostat, there was a significant regression in cardiac remodelling, cardiac hypertrophy, and fibrosis in TAC rats. Additionally, pressure overload-induced renal fibrosis and activity of RAS-related components were increased in TAC rats, and were decreased on treatment with mocetinostat. The present study indicates that mocetinostat, an HDAC inhibitor, has cardiorenal protective effects in rats with TAC-induced pressure overload cardiac hypertrophy and offers a promising therapeutic agent for hypertension-related diseases.

30 May 2023 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
MBMiju Bae
Miju Bae
SCSung Woon Chung
Sung Woon Chung
JLJonggeun Lee
Jonggeun Lee
EKEunji Kim
Eunji Kim
GKGayeon Kang
Gayeon Kang
MJMoran Jin
Moran Jin
Miju Bae, Ph.D., Sung Woon Chung, M.D., Ph.D., Jonggeun Lee, M.D., Eunji Kim, M.D., Gayeon Kang, M.D., Moran Jin, M.D.. J Chest Surg 2023;56:328-35. https://doi.org/10.5090/jcs.22.148

9 October 2012 in The Korean Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
CLChung Won Lee
Chung Won Lee
SCSung Woon Chung
Sung Woon Chung
SSSeunghwan Song
Seunghwan Song
MBMi Ju Bae
Mi Ju Bae
UHUp Huh
Up Huh
JKJae Hun Kim
Jae Hun Kim
Lee CW, et al. Korean J Thorac Cardiovasc Surg. 2012 Oct;45(5):330-333. http://dx.doi.org/10.5090/kjtcs.2012.45.5.330

5 December 2014 in The Korean Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
MBMi Ju Bae
Mi Ju Bae
JLJong Geun Lee
Jong Geun Lee
SCSung Woon Chung.
Sung Woon Chung.
CLChung Won Lee
Chung Won Lee
CKChang Won Kim
Chang Won Kim
This study reports the result of endovascular treatment for arterial occlusive disease limited to femoropopliteal lesions, focusing on the recurrence of symptoms instead of patency. This was a retrospective, single-center study. From April 2007 to November 2011, 48 limbs in 38 patients underwent endovascular stenting or balloon angioplasty to treat femoropopliteal arterial occlusive disease. The factors affecting the recurrence of symptoms were analyzed. The mean age of the patients was 69.60±7.62 years. Among the baseline characteristics of the patients, initial hyperlipidemia was the most important factor affecting the recurrence of symptoms (relative risk=5.810, p=0.031). The presence of a dorsal arch was also a significant factor (relative risk=0.675, p=0.047). The major factors that affect the recurrence of symptoms after endovascular treatment for femoropopliteal arterial occlusive lesions are hyperlipidemia and the presence of a dorsal arch. Therefore, the usage of lipid-lowering agents after endovascular treatment and taking the presence of a dorsal arch into consideration are important elements of managing the recurrence of symptoms.